California, USA-based clinical-stage biotech Braveheart Bio has announced its launch with $185 million in Series A financing, ...
With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...
The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...
Leadership brings experience in company building, advancing late-stage clinical programs, and deep understanding of cardiovascular drug developmentCompany intends to rapidly advance BHB-1893 into late ...
Investors have once again turned to Chinese pharmaceutical company Jiangsu Hengrui to create a new biotech startup, this time ...
Biogen CEO Chris Viehbacher and Travis Murdoch — fellow Canadians — hit it off when Biogen last year bought Murdoch's HI-Bio ...
You never forget your first day on a movie set… particularly when that first day involves 2,000 extras screaming bloody murder. That’s how songwriter-turned-author-turned-screenwriter Randall Wallace ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback